In January 2016, Independence Blue Cross and NantHealth announced the nation's first coverage for a whole genome sequencing and proteome molecular diagnostic platform, but it's mostly slipped under the radar since then. What's going on?
NantWorks, the company of Patrick Soon-Shiong, has acquired a majority stake in Integrity Healthcare, Verity Health System's management company. Through the deal, NantWorks will become the operator of six California hospitals, including St. Vincent Medical Center.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
After his recent appointment to a national health IT advisory committee, Soon-Shiong explained how his life's work is now converging towards major advances in cancer and healthcare more broadly.
NantWorks' Patrick Soon-Shiong and leaders from Norton Healthcare and Sutter Health have been appointed to a new Health IT Advisory Committee formed through the passing of the 21st Century Cures Act.
After 15 years of research, Patrick Soon-Shiong has unveiled the Nant Cancer Vaccine, bringing together myriad biology and technology advances made throughout his NantWorks empire.
NantHealth, the health IT, genomics and analytics division of Dr. Patrick Soon-Shiong’s NantWorks business empire, raised $91 million in the IPO.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Some view this approach as already outmoded, is too optimistic to be realistic, and wrongly states cancer as a single disease - when it results from a multitude of factors and presents in countless ways.
Another load of cash - and little further insight - is on the books for Patrick Soon-Shiong cancer immunotherapy startup NantCell.
Dr. Patrick Soon-Shiong made it sound like he finally had all the pieces in place to create a healthcare analytics and precision-medicine powerhouse that incorporates genomics, health records, patient history and claims data to produce prospective, actionable decision support across the whole healthcare continuum.
Dr. Patrick Soon-Shiong confirmed the plan in an interview with the Los Angeles Times. His NantKwest immuno-oncology company has lost half its value since a July IPO.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Precision Biologics, a Maryland developer of cancer immunotherapies and companion diagnostics, just received a $50 million investment from billionaire Patrick Soon-Shiong's mega-startup, NantWorks.
In its second Amgen partnership this year, NantWorks - billionaire Patrick Soon-Shiong's sprawling healthcare company - is working on a Phase 2 small molecule drug that treates gastric cancer.
Dr. Patrick Soon-Shiong has two more fundraises under his companies' belt: According to an SEC filing, immuno-oncology startup NantCell has raised $100 million and precision medicine startup NantOmics has raised $150 million.
Isn't Theranos supposed to be a smart company? The MIT Technology Review highlights each year what it considers the world's "smartest companies." Understandably, several have been left out.
The mysterious company just allocated $75 million to its NantCell division - putting some serious funding behind its precision medicine and cancer immunotherapy efforts.